- Home
- TROW vs BIIB Comparison
TROW vs BIIB Comparison
Compare TROW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROW
- BIIB
- Stock Information
- Founded
- TROW 1937
- BIIB 1978
- Country
- TROW United States
- BIIB United States
- Employees
- TROW N/A
- BIIB N/A
- Industry
- TROW Investment Bankers/Brokers/Service
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TROW Finance
- BIIB Health Care
- Exchange
- TROW Nasdaq
- BIIB Nasdaq
- Market Cap
- TROW 26.2B
- BIIB 25.1B
- IPO Year
- TROW N/A
- BIIB 1991
- Fundamental
- Price
- TROW $117.07
- BIIB $149.02
- Analyst Decision
- TROW Sell
- BIIB Buy
- Analyst Count
- TROW 12
- BIIB 26
- Target Price
- TROW $116.25
- BIIB $248.00
- AVG Volume (30 Days)
- TROW 1.5M
- BIIB 1.6M
- Earning Date
- TROW 02-06-2025
- BIIB 02-11-2025
- Dividend Yield
- TROW 4.24%
- BIIB N/A
- EPS Growth
- TROW 30.16
- BIIB 10.05
- EPS
- TROW 9.13
- BIIB 11.06
- Revenue
- TROW $6,911,100,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- TROW $13.10
- BIIB N/A
- Revenue Next Year
- TROW $5.46
- BIIB N/A
- P/E Ratio
- TROW $12.82
- BIIB $13.47
- Revenue Growth
- TROW 8.96
- BIIB N/A
- 52 Week Low
- TROW $100.49
- BIIB $145.07
- 52 Week High
- TROW $125.81
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- TROW 45.43
- BIIB 32.44
- Support Level
- TROW $112.11
- BIIB $145.07
- Resistance Level
- TROW $116.77
- BIIB $149.92
- Average True Range (ATR)
- TROW 2.20
- BIIB 3.81
- MACD
- TROW -0.94
- BIIB 0.05
- Stochastic Oscillator
- TROW 36.20
- BIIB 22.51
About TROW T. Rowe Price Group Inc.
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load us and international stock, hybrid, bond, and money market funds. At the end of August 2024, the firm had $1.612 trillion in managed assets, composed of equity (51%), balanced (34%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a us-based asset manager, deriving less than 10% of its AUM from overseas.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.